Contributions
Abstract: P674
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Lipoic acid (LA) is an inexpensive, orally active antioxidant that can treat experimental acute optic neuritis (AON) and experimental autoimmune encephalomyelitis effectively. Recently, LA showed slower whole brain atrophy in secondary progressive multiple sclerosis, suggesting a neuroprotective effect. Thinning of the retinal nerve fiber layer (RNFL) as detected by optical coherence tomography (OCT) occurs 3-6 months following AON, indicating retinal nerve ganglion cells axonal degeneration. While corticosteroids speed AON recovery, neuroprotective therapies for AON are lacking.
Goal: To determine whether LA is neuroprotective in AON.
Methods: We conducted a double-masked, placebo-controlled 24-week long pilot trial to assess the effectiveness of LA in AON. Subjects were randomized within 14 days of AON diagnosis to receive LA (1200 mg orally once a day) or placebo for 6 weeks. The outcome measures included: Primary - difference in affected eye RNFL thickness from baseline to 24 weeks post-enrollment; Secondary - difference in affected eye RNFL thickness from baseline to 12 weeks post-enrollment, changes from baseline to 12 and 24 week in visual acuity, low-contrast sensitivity, and visual field.
Results: We enrolled 30 subjects (average age - 38.6 years (SD: 10.3); 63% female) with 3 who were lost to follow-up. 13 (43%) of the subjects received steroid treatment. Mean baseline RNFL thickness in the affected eye and unaffected eye at: Baseline - 106.3 µm (SD: 23.1) and 96.4 µm (SD: 10.5); 12 week - 88.5 µm (SD: 18.7) and 96 µm (SD: 13.3); 24 week - 79.4 µm (SD: 22.8) and 95.9 µm (SD: 15.2) respectively. Treatment was tolerated well. The last subject exits the study in June 2016.
Conclusions: The results of the trials, including effects of LA on changes in RNLF and other outcome measures will be presented.
Sponsor: National Multiple Sclerosis Society Foundation, Race to Erase MS Foundation
Supported By: Pure Encapsulations®
Disclosure:
Vijayshree Yadav: nothing to disclose
Michele Mass: nothing to disclose
Gail Marracci: nothing to disclose
Rohan Wanchu: nothing to disclose
Allison Fryman: nothing to disclose
Bill Hills: nothing to disclose
Julie Falardeau: nothing to disclose
Dennis Bourdette: nothing to disclose
Abstract: P674
Type: Poster
Abstract Category: Therapy - disease modifying - Neuroprotection
Background: Lipoic acid (LA) is an inexpensive, orally active antioxidant that can treat experimental acute optic neuritis (AON) and experimental autoimmune encephalomyelitis effectively. Recently, LA showed slower whole brain atrophy in secondary progressive multiple sclerosis, suggesting a neuroprotective effect. Thinning of the retinal nerve fiber layer (RNFL) as detected by optical coherence tomography (OCT) occurs 3-6 months following AON, indicating retinal nerve ganglion cells axonal degeneration. While corticosteroids speed AON recovery, neuroprotective therapies for AON are lacking.
Goal: To determine whether LA is neuroprotective in AON.
Methods: We conducted a double-masked, placebo-controlled 24-week long pilot trial to assess the effectiveness of LA in AON. Subjects were randomized within 14 days of AON diagnosis to receive LA (1200 mg orally once a day) or placebo for 6 weeks. The outcome measures included: Primary - difference in affected eye RNFL thickness from baseline to 24 weeks post-enrollment; Secondary - difference in affected eye RNFL thickness from baseline to 12 weeks post-enrollment, changes from baseline to 12 and 24 week in visual acuity, low-contrast sensitivity, and visual field.
Results: We enrolled 30 subjects (average age - 38.6 years (SD: 10.3); 63% female) with 3 who were lost to follow-up. 13 (43%) of the subjects received steroid treatment. Mean baseline RNFL thickness in the affected eye and unaffected eye at: Baseline - 106.3 µm (SD: 23.1) and 96.4 µm (SD: 10.5); 12 week - 88.5 µm (SD: 18.7) and 96 µm (SD: 13.3); 24 week - 79.4 µm (SD: 22.8) and 95.9 µm (SD: 15.2) respectively. Treatment was tolerated well. The last subject exits the study in June 2016.
Conclusions: The results of the trials, including effects of LA on changes in RNLF and other outcome measures will be presented.
Sponsor: National Multiple Sclerosis Society Foundation, Race to Erase MS Foundation
Supported By: Pure Encapsulations®
Disclosure:
Vijayshree Yadav: nothing to disclose
Michele Mass: nothing to disclose
Gail Marracci: nothing to disclose
Rohan Wanchu: nothing to disclose
Allison Fryman: nothing to disclose
Bill Hills: nothing to disclose
Julie Falardeau: nothing to disclose
Dennis Bourdette: nothing to disclose